Health · Pharma & Biotech · 3 hrs ago
FDA proposes faster approval path for some personalized gene therapies
The FDA proposed a faster approval path for some gene therapies designed for people with rare diseases.
These treatments are tailored to correct different mutations in the same disease-causing gene.
Because each mutation can be extremely rare, running a separate clinical trial for every treatment may be impractical.
Under the draft plan, a company could first seek approval for a therapy targeting one mutation through a more traditional process.
It could then seek approval for treatments targeting other mutations using laboratory data, if those changes fit within a defined range set out in the original application.
The plan aims to make it more practical for drugmakers to develop treatments for patients who might otherwise have few options.
The proposal is still draft guidance, and the FDA is also working on a broader initiative to set standards for rare diseases.
The FDA published draft guidance proposing a faster approval path for some personalized gene therapies.
The plan focuses on treatments that target different mutations in the same disease-causing gene.
After approval for a therapy targeting one mutation, a drugmaker could seek clearance for other mutations using laboratory data rather than a new clinical study.
The FDA says the approach could address cases where mutations are so rare that traditional clinical trials are impractical or impossible.
The proposal is part of broader agency efforts to encourage treatments for rare diseases.
- Who
- The Food and Drug Administration.
- What
- It proposed a pathway to streamline approval of some personalized gene therapies.
- When
- Tuesday, October 27, 2026.
- Where
- Not stated.
- Why
- To support development and access for rare-disease treatments when traditional clinical trials may be impractical or impossible.
This story does not have two clearly opposing sides.
Scientists worked together to develop a medicine for critically ill baby KJ Muldoon in a few months.
The FDA published draft guidance to streamline approvals for some individualized gene therapies.
The FDA was due to hold a meeting at its White Oak campus about its Rare Disease Framework Initiative.
- Agency
- Food and Drug Administration
- Proposal
- Draft guidance for some individualized gene therapies
- Potential later approvals
- Laboratory data instead of a new clinical study
- Target
- Different mutations in the same disease-causing gene
- Earlier example
- Medicine developed for KJ Muldoon in May 2025
3 sources
What people are saying
It’s sort of putting a flag in the ground and saying, ‘This is important,’
All of this is completely supported by the science of base editing,
But it’s still exhilarating to see the FDA crafting such a forward-looking approach.
plug and play
Posts on X
Exciting updates on gene editing support from the U.S. Government! We didn’t plan this… but just a few hours after our conference call outlining Beam’s vision to deliver increasingly customized genetic correction therapies to patients, even more news hit